ARTICLE | Company News
Hydra, Boehringer Ingelheim deal
April 28, 2014 7:00 AM UTC
Hydra partnered with Boehringer to develop small molecule inhibitors against transient receptor potential cation channel subfamily C member 4 (TRPC4) and TRPC5 to treat CNS diseases and disorders. H...